Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
Holding ALKS?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.75Last Year’s EPS
$0.22Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 24, 2024
|% Change Since: 6.68%
|Next Earnings Date:Feb 13, 2025
Earnings Call Sentiment|Neutral
The earnings call presented strong growth metrics in the proprietary product portfolio, especially VIVITROL and LYBALVI, and a solid financial position. However, there are challenges in the schizophrenia market and expected declines in royalty and manufacturing revenues, impacting future profitability.Company Guidance
During the Alkermes Q3 2024 earnings call, the company provided detailed guidance, highlighting several key metrics. The aggregate net sales of proprietary products reached $273 million, marking an 18% year-over-year growth. VIVITROL's net sales were $113.7 million, with a 14% increase from the previous year, and the full-year sales are expected to be between $410 million to $430 million. ARISTADA's net sales were reported at $84.7 million, with expectations to be towards the lower end of $340 million to $360 million for the year. LYBALVI generated $74.7 million in net sales, with projections for the full year in the range of $275 million to $295 million. The company reiterated its financial expectations for 2024, with a focus on profitability. For 2025, Alkermes plans to manage the business for significant profitability and cash flow, with anticipated EBITDA surpassing $200 million, despite the impact of a $200 million reduction in royalty and manufacturing revenues. The company concluded the third quarter with $927.8 million in cash and investments, and it has so far deployed $116 million for share repurchases as part of a $400 million buyback program.Strong Growth in Proprietary Product Portfolio
Aggregate net sales of $273 million, reflecting an 18% year-over-year growth, with expectations of exceeding $1 billion in proprietary net sales for 2024.
VIVITROL Sales Performance
VIVITROL's net sales in Q3 were $113.7 million, a 14% year-over-year increase, driven by demand in the alcohol dependence indication.
LYBALVI Market Expansion
LYBALVI generated net sales of $74.7 million in Q3, with total prescriptions growing 5% sequentially and 37% year-over-year.
Financial Position and Share Repurchase
Ended Q3 with $927.8 million in cash and total investments; deployed approximately $116 million to repurchase 4.4 million shares.
Advancement of ALKS 2680
Positive Phase 1b data in narcolepsy type 1, type 2, and idiopathic hypersomnia, quickly progressing into Phase 2 studies.
---
ALKS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ALKS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 24, 2024 | $27.85 | $26.85 | -3.59% |
| Jul 24, 2024 | $25.00 | $26.51 | +6.04% |
| May 01, 2024 | $24.54 | $24.01 | -2.16% |
| Feb 15, 2024 | $27.99 | $32.56 | +16.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Alkermes (ALKS) report earnings?
Alkermes (ALKS) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Alkermes (ALKS) earnings time?
Alkermes (ALKS) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALKS EPS forecast?
ALKS EPS forecast for the fiscal quarter 2024 (Q4) is $0.75.
---